Hormonal regulation of renal sodium and water excretion during normotensive sodium loading in conscious dogs

NIELS C. F. SANDGAARD, JENS LUNDBÆK ANDERSEN, AND PETER BIE. Hormonal regulation of renal sodium and water excretion during normotensive sodium loading in conscious dogs. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 278: R11–R18, 2000.—Saline was infused intravenously for 90 min to normal, sodium-replete conscious dogs at three different rates (6, 20, and 30 µmol·kg⁻¹·min⁻¹) as hypertonic solutions (HyperLoad-6, HyperLoad-20, and HyperLoad-30, respectively) or as isotonic solutions (IsoLoad-6, IsoLoad-20, and IsoLoad-30, respectively). Mean arterial blood pressure did not change with any infusion of 6 or 20 µmol·kg⁻¹·min⁻¹. During HyperLoad-6, plasma vasopressin increased by 30%, although the increase in plasma osmolality (1.0 mosmol/kg) was insignificant. During HyperLoad-20, plasma ANG II decreased from 14 ± 2 to 7 ± 2 pg/ml and sodium excretion increased markedly (2.3 ± 0.8 to 19 ± 8 µmol/min), whereas glomerular filtration rate (GFR) remained constant. IsoLoad-20 decreased plasma ANG II similarly (13 ± 3 to 7 ± 1 pg/ml) concomitant with an increase in GFR and a smaller increase in sodium excretion (1.9 ± 1.0 to 11 ± 6 µmol/min). HyperLoad-30 and IsoLoad-30 increased mean arterial blood pressure by 6–7 mmHg and decreased plasma ANG II to ~6 pg/ml, whereas sodium excretion increased to ~60 µmol/min. The data demonstrate that, during slow sodium loading, the rate of excretion of sodium may increase 10-fold without changes in mean arterial blood pressure and GFR and suggest that the increase may be mediated by a decrease in plasma ANG II. Furthermore, the vasopressin system may respond to changes in plasma osmolality undetectable by conventional osmometry.

Angiotensin II; volume expansion; vasopressin; blood pressure; natriuresis.

The relative importance of the humoral, hemodynamic, and nervous mechanisms in the regulation of renal sodium excretion is still controversial. The relative roles of the arterial blood pressure and the renin-angiotensin-aldosterone system in providing sodium homeostasis are particularly complex. Recently, we demonstrated (4) that a sodium load simulating daily sodium intake induced natriuresis concomitant with a decrease in plasma ANG II level and a small, but significant, increase in arterial blood pressure. Under these circumstances, the natriuresis may be explained by the decrease in plasma ANG II level and by the increase in arterial blood pressure. Sodium loading was also performed during normotensive ANG II clamping, i.e., a constant infusion of ANG II sufficient to normalize arterial blood pressure during control conditions. Under these conditions, >90% of the natriuretic response to sodium loading was blocked, indicating a pivotal role of ANG II in the control of renal sodium excretion. However, the procedure of sodium loading still increased arterial blood pressure. Different methods may be used to isolate the effect of an increase in renal perfusion pressure, including aortic cuffs (22) and pharmacological pressure control (1). In this study we chose to infuse different sodium loads at rates that are too small to change arterial blood pressure and to measure the concomitant endocrine and renal excretory changes. In this way it might be possible to separate the effects of humoral factors from those of changes in arterial blood pressure without interfering with intrarenal hemodynamics or constricting the renal artery. To our knowledge the responses to such small, slow sodium loads in conscious dogs have not previously been reported.

Methods

Animals

The experiments were performed in conscious female Beagle dogs weighing 11.5–16 kg. The dogs were kept on a fixed diet (Special Diets Services, Witham, UK) and received one meal a day at around 1400. Mean daily sodium intake was 2.2 ± 0.1 mmol/kg body wt (mean ± SE). The dogs had free access to tap water. Before the study, several surgical interventions were approved by the Danish Animal Experiments Inspectorate.

Experimental Protocol

The same six dogs were used for all experiments, and in the last two infusion series (see below) one more dog was included. In each dog, experiments were performed at intervals of >1 wk. At midnight before the experiment, an electric valve controlled by a timer interrupted the water supply. On the experimental day, the dog was transferred to the laboratory and prepared for study as previously described (4). Briefly, catheters were placed in a central vein, in a carotid artery, and in the bladder. After a 30-min control period, isotonic or hypertonic salt loading was initiated and continued for 90 min (t = 120 min) followed by a 30-min recovery period.
The first sample of arterial blood was obtained at \( t = -5 \) min; subsequent samples were obtained 25 min into each sampling period. Samples of 1 ml drawn at \( t = -5 \) min, \( t = 55 \) min, and \( t = 85 \) min were used to measure the plasma creatinine, whereas electrolyte, ANG II, vasopressin, and creatinine levels were measured from 15-ml samples obtained at \( t = 25 \) min, \( t = 115 \) min, and \( t = 145 \) min.

The renal, hemodynamic, and humoral responses to intravenous sodium loads of different magnitude were investigated in seven experimental series of six or seven experiments.

**IsoLoad-6.** An intravenous infusion of isotonic NaCl solution (154 mmol/l) was initiated at \( t = 30 \) min and continued for 90 min at a rate of \( 6 \, \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} \), i.e., at a flow rate of 0.039 ml·kg\(^{-1}\)·min\(^{-1}\). Saline loading was followed by a 30-min recovery period \((n = 6)\).

**HyperLoad-6.** This experimental series was identical to the IsoLoad-6 series, except that the same sodium load \((6 \, \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1})\) was administered as a hypertonic \((2 \, \text{mol/l NaCl})\) solution. Thus the infusion rate was 0.003 ml·kg\(^{-1}\)·min\(^{-1}\) \((n = 6)\).

**IsoLoad-20.** The IsoLoad-20 series was identical to the IsoLoad-6 series, except that isotonic NaCl solution (154 mmol/l) was infused at a rate of 20 \( \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} \), corresponding to 0.13 ml·kg\(^{-1}\)·min\(^{-1}\) \((n = 6)\).

**HyperLoad-20.** The sodium load of 20 \( \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} \) NaCl was administered as a hypertonic \((2 \, \text{mol/l NaCl})\) solution from \( t = 30 \) to 120 min. The rate of infusion was 0.01 ml·kg\(^{-1}\)·min\(^{-1}\) \((n = 6)\).

**IsoLoad-30.** IsoLoad-30 involved infusion of isotonic NaCl solution (154 mmol/l) for 90 min at a rate of 30 \( \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} \), i.e., at a rate of 0.195 ml·kg\(^{-1}\)·min\(^{-1}\) \((n = 7)\).

**HyperLoad-30.** A sodium load of 30 \( \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} \) NaCl was administered as a hypertonic \((2 \, \text{mol/l NaCl})\) solution from \( t = 30 \) to 120 min. Thus the rate of infusion was 0.015 ml·kg\(^{-1}\)·min\(^{-1}\) \((n = 7)\).

Arterial blood pressure was measured continuously by a pressure transducer (Statham P50, Gould) connected to a patient monitor (Dialogue 2000, Danica Elektronik, Rødovre, Denmark). This provided analog-to-digital conversion at a rate of 300 Hz on the basis of a 7-s time window and calculation of mean arterial blood pressure. Heart rate was calculated from the electrocardiogram signal. Data were sampled from the monitor every 10 s by computer and subsequently averaged over 30-min periods.

**Analyses**

The concentrations of sodium and potassium ions in plasma and urine were measured by flame photometry (model 243, Instrumentation Laboratory). Plasma and urine osmolality was determined by freezing-point depression (model 3D3, Advanced Instruments, Needham Heights, MA). Plasma protein concentration was measured by a refractometer (model T2-NE, Atago, Tokyo, Japan). Concentrations of creatinine in urine and plasma were measured by the Jaffe reaction, as described by Bonsnes and Taussky (5).

The analyses of hormone levels in plasma were performed by radioimmunoassay after extraction as previously described (10).

Immunoreactivity of vasopressin in extracts of plasma was measured using an antibody (AB3096) produced in this laboratory. The antibody and the method have been described earlier (4, 11). The detection limit was 0.2 pg/ml, and the mean recovery of unlabeled vasopressin was 68%. Intra- and interassay coefficients of variation were <8%.

To determine ANG II immunoreactivity in plasma, a specific antibody (Ab-5-030682) was used as described earlier (4). Detection limit was 1.4 pg/ml, and the mean recovery of unlabeled ANG II was 88%. Intraassay coefficient of variation was 5%, and interassay coefficient of variation was 7%.

**Statistics**

Data are presented as means ± SE. The results were evaluated by one-way ANOVA for repeated measurements within and between groups. Possible inhomogeneity of variance was assessed by use of Levene's test. When inhomogeneity was present, the data were logarithmically transformed before analysis. If the results of the ANOVA were significant \((P < 0.05)\), all differences between means were investigated systematically by Newman-Keuls test. P values smaller than 0.05 were considered to indicate significance.

**RESULTS**

**Systemic Hemodynamics**

In all series, low and constant control levels of mean arterial blood pressure and heart rate were observed. During and after administration of isotonic and hypertonic saline at rates of 6 and 20 \( \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} \), mean arterial blood pressure and heart rate remained unchanged (Table 1). HyperLoad-30 increased mean arterial blood pressure but did not change heart rate. IsoLoad-30 increased mean arterial blood pressure to similar values while heart rate was elevated, indicating activity of the Bainbridge reflex (Table 1).

**Plasma Electrolytes, Osmolality, and Protein Concentration**

During HyperLoad-6 and IsoLoad-6, no significant changes occurred in plasma sodium and potassium concentrations or in plasma osmolality (Table 2 and Fig. 1). In both series, plasma protein concentration exhibited small, but significant, decreases (Table 2). HyperLoad-20 increased plasma sodium concentration by 1% and plasma osmolality by 6 mosmol/kg, whereas HyperLoad-30 increased plasma sodium by 4 mmol/l and plasma osmolality by 7 mosmol/kg (Table 2 and Fig. 1). IsoLoad-20 and IsoLoad-30 decreased plasma protein concentration without changes in plasma sodium, plasma potassium, and plasma osmolality.

**Hormones**

During HyperLoad-6 experiments, plasma vasopressin was increased by 30% \((0.84 ± 0.05 to 1.11 ± 0.09 \text{ pg/ml})\) despite the absence of measurable changes in plasma osmolality (Fig. 1). The larger, and measurable, osmotic stimuli occurring during the HyperLoad-20 and HyperLoad-30 series further augmented plasma vasopressin to 3.21 ± 0.46 pg/ml, respectively. In all hypertonic series, plasma vasopressin remained elevated in the recovery period. In IsoLoad-6, -20, and -30 series, plasma vasopressin levels were unchanged throughout the experiment (Fig. 1).

During HyperLoad-6 and IsoLoad-6 experiments, no changes were observed in the plasma levels of ANG II (Fig. 2). In HyperLoad-20 and IsoLoad-20 series, plasma
ANG II decreased to 50% of control (14.2 ± 2.2 to 7.2 ± 1.9 pg/ml and 12.8 ± 1.7 to 6.0 ± 0.6 pg/ml, respectively) and remained at this level throughout the experiments. When sodium loading was given at the rate of 30 μmol·kg⁻¹·min⁻¹ (HyperLoad-30 and IsoLoad-30), there was a tendency toward larger decreases in plasma ANG II levels (Fig. 2).

Renal Variables

Creatinine clearance was used as a measure of GFR (Table 3). In the HyperLoad-6 and HyperLoad-20 series, mean GFR values were remarkably steady at ~40 ml/min and no trend toward a change was observed. During IsoLoad-6 experiments, GFR exhibited a transient increase, and, in the IsoLoad-20 series, the increase in GFR persisted for the remainder of the experiment (Table 3). Administration of HyperLoad-30 and IsoLoad-30 increased GFR by similar amounts, i.e., by 15 and 13%, respectively (Table 3).

Urine flows and free water clearances were stable at ~0.15 and ~0.35 ml/min, respectively, during and after sodium and water loads of HyperLoad-6 and IsoLoad-6 (Fig. 1). HyperLoad-20 decreased free water clearance from ~0.34 ± 0.02 to ~0.47 ± 0.05 ml/min, whereas no changes were observed in urine flow. IsoLoad-20 increased urine flow from 0.12 ± 0.02 to 0.20 ± 0.04 ml/min concomitant with a small decrease in free water clearance (Fig. 1). The large salt load (HyperLoad-30) markedly reduced free water clearance concurrent with a substantial increase in plasma vasopressin levels. However, urine flow in this series was elevated from 0.11 ± 0.02 to 0.23 ± 0.04 ml/min and further to 0.37 ± 0.08 ml/min during recovery period, because the osmolar clearance increased more than free water clearance fell. IsoLoad-30 augmented urine flow some fivefold (0.12 ± 0.01 to 0.58 ± 0.17 ml/min), whereas free water clearance exhibited a small transient decrease (Fig. 1).

The effects of sodium and water loading on renal sodium excretion are shown in Fig. 2B. The overall pattern shows a clear-cut dose-response relationship within the range of 6–30 μmol·kg⁻¹·min⁻¹. No changes were observed during infusion of HyperLoad-6 and

Table 2. Plasma electrolytes and protein concentration

<table>
<thead>
<tr>
<th>Experimental Series</th>
<th>Time, min</th>
<th>Control</th>
<th>HyperLoad-6</th>
<th>IsoLoad-6</th>
<th>HyperLoad-20</th>
<th>IsoLoad-20</th>
<th>HyperLoad-30</th>
<th>IsoLoad-30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>146.0 ± 0.4</td>
<td>145.2 ± 0.6</td>
<td>144.8 ± 0.3</td>
<td>146.2 ± 0.7</td>
<td>144.7 ± 0.8</td>
<td>145.0 ± 1.0</td>
<td>144.0 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>115</td>
<td>145.0 ± 0.4</td>
<td>145.5 ± 0.4</td>
<td>143.8 ± 0.4</td>
<td>147.5 ± 0.4†</td>
<td>144.3 ± 0.9</td>
<td>149.0 ± 1.0†</td>
<td>144.0 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>145</td>
<td>145.3 ± 0.6</td>
<td>145.7 ± 0.3</td>
<td>144.0 ± 0.4</td>
<td>147.7 ± 0.2†</td>
<td>144.7 ± 0.6</td>
<td>148.0 ± 1.0†</td>
<td>143.0 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>4.1 ± 0.1</td>
<td>4.1 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>4.1 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>4.1 ± 0.1</td>
<td>4.0 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>115</td>
<td>4.2 ± 0.1</td>
<td>4.1 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>3.9 ± 0.0</td>
<td>4.0 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>4.0 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>145</td>
<td>4.1 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>4.0 ± 0.1</td>
<td>4.1 ± 0.0</td>
<td>4.0 ± 0.0</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>5.5 ± 0.1</td>
<td>5.3 ± 0.1</td>
<td>5.2 ± 0.1</td>
<td>5.5 ± 0.1</td>
<td>5.5 ± 0.1</td>
<td>5.7 ± 0.1</td>
<td>5.6 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>115</td>
<td>5.5 ± 0.1</td>
<td>5.2 ± 0.1*</td>
<td>5.0 ± 0.1*</td>
<td>5.2 ± 0.1*</td>
<td>5.0 ± 0.2*</td>
<td>5.2 ± 0.1*</td>
<td>5.1 ± 0.1*</td>
</tr>
<tr>
<td></td>
<td>145</td>
<td>5.4 ± 0.1</td>
<td>5.1 ± 0.1*</td>
<td>5.0 ± 0.1*</td>
<td>5.1 ± 0.1*</td>
<td>5.1 ± 0.1*</td>
<td>5.2 ± 0.1*</td>
<td>5.2 ± 0.1*</td>
</tr>
</tbody>
</table>

Values are means ± SE (n = 6), except in HyperLoad-30 and IsoLoad-30 (n = 7). Saline was infused for 90 min from t = 30 min to t = 120 min. *Significantly different from preinfusion level (P < 0.05); †significantly different from control series (P < 0.05).
IsoLoad-6, but sodium excretion was elevated above control level in the recovery period of HyperLoad-6 series. During the HyperLoad-20 and IsoLoad-20 series, renal sodium excretion increased to 19 ± 6 and 11 ± 6 µmol/min, respectively, and was further augmented in the recovery period (26 ± 9 and 14 ± 6 µmol/min, respectively). Sodium excretion during the HyperLoad-30 and IsoLoad-30 series exhibited large, but similar, increases during the infusion periods (61 ± 13 and 65 ± 17 µmol/min, respectively). In contrast, during the recovery period, sodium excretion rate continued to increase in the HyperLoad-30 series (to 83 ± 19 µmol/min), whereas it leveled off in the IsoLoad-30 series (63 ± 16 µmol/min). Comparing the results of hypertonic infusions with those of isotonic infusions, there was a trend toward higher levels of sodium excretion in the recovery period in the hypertonic series. In most series, GFR did not increase persistently. In other series, the relative changes in GFR were much smaller than the corresponding changes in the rates of excretion of sodium. Therefore, the pattern of changes in fractional sodium excretion was very similar to that of absolute sodium excretion (Table 3).

**DISCUSSION**

The purpose of this study was to identify the relative importance of changes in arterial blood pressure and other natriuretic factors by measuring the response to sodium loads, which were too small to change arterial blood pressure. These circumstances were achieved by administration over 90 min of sodium loads increasing from 25% of daily sodium intake. With the use of this approach, under highly standardized conditions it was possible to increase renal sodium excretion by ~10-fold without any change in mean arterial blood pressure, heart rate, or GFR.

In the control situations, mean arterial blood pressure was stable, averaging 108 mmHg (Table 1). A threshold for blood pressure elevation by saline infusion was apparent as administration of 6 and 20 µmol·kg⁻¹·min⁻¹ did not change mean arterial blood pressure, and infusion of 30 µmol·kg⁻¹·min⁻¹ increased blood pressure by ~10 mmHg.

Saline infusions were performed from t = 30 to 120 min. Values are means ± SE. *Significantly different from preinfusion level (P < 0.05); †significantly different from control series (P < 0.05).
increased mean arterial blood pressure by 6–7 mmHg. Over 90 min, the two highest rates correspond to sodium loads of 80 and 125% of daily sodium intake. The effects on mean arterial blood pressure appear to be dependent on the infusion rate of sodium rather than the total amount of sodium infused. This follows from the finding that mean arterial blood pressure did not change at all during the full 90 min of HyperLoad-20 or IsoLoad-20 but increased significantly well within the first 60 min of infusion in the HyperLoad-30 and IsoLoad-30 series. The amounts of sodium infused within these time frames are identical. So the blood pressure of these conscious dogs was increased by infusion of NaCl at rates larger than a threshold, somewhere between 20 and 30 µmol·kg⁻¹·min⁻¹. Other reports of the effects of acute sodium loading on mean arterial blood pressure in dogs have not provided comparable results. Cowley et al. (7) showed that a 10-min volume expansion with 400 ml isotonic saline in conscious dogs, corresponding to ~410 µmol·kg⁻¹·min⁻¹, increased mean arterial blood pressure by 6 mmHg, whereas the same load for 30 min (~140 µmol·kg⁻¹·min⁻¹) did not change mean arterial blood pressure (8). Kaczmarczyk et al. (15) reported an increase of 10 mmHg in mean arterial pressure after infusion of 150 µmol·kg⁻¹·min⁻¹ of sodium chloride to conscious dogs for 60 min, whereas Pinilla et al. (21) infused ~170 µmol·kg⁻¹·min⁻¹ for 45 min in anesthetized dogs without measuring any change in mean arterial blood pressure. Recently, Krieger and Romero (16) increased mean arterial blood pressure by 14 mmHg in anesthetized dogs with a load of 130 µmol·kg⁻¹·min⁻¹ sodium for 60 min. There is no obvious explanation for the difference between these results; however, it might well be due to differences between the experimental conditions, particularly with regard to sodium intake and volume status. Nevertheless, our data clearly demonstrate that infusion of NaCl at rates from 30 µmol·kg⁻¹·min⁻¹ may cause immediate blood pressure increases and, in the case of isotonic loading, also tachycardia.

During and after the infusion period in IsoLoad-20 and HyperLoad-20 series, we observed a natriuretic response without any change in mean arterial blood pressure. In the latter experiment, the natriuresis occurred without increases in GFR, possibly because the effects of the sodium loading were counterbalanced by the decrease in the activity of the renin-angiotensin system. Other natriuretic factors must, therefore, be responsible for this natriuresis. An obvious candidate is

**Table 3. Renal variables**

<table>
<thead>
<tr>
<th>Time, min</th>
<th>Control</th>
<th>HyperLoad-6</th>
<th>IsoLoad-6</th>
<th>HyperLoad-20</th>
<th>IsoLoad-20</th>
<th>HyperLoad-30</th>
<th>IsoLoad-30</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–30</td>
<td>1019 ± 160</td>
<td>1085 ± 122</td>
<td>1301 ± 106</td>
<td>1443 ± 181</td>
<td>1296 ± 134</td>
<td>1325 ± 149</td>
<td>1228 ± 151</td>
</tr>
<tr>
<td>30–60</td>
<td>1214 ± 132</td>
<td>1352 ± 188</td>
<td>1319 ± 121</td>
<td>1191 ± 118</td>
<td>1440 ± 205</td>
<td>1519 ± 259</td>
<td>996 ± 79*</td>
</tr>
<tr>
<td>60–90</td>
<td>1281 ± 154</td>
<td>1280 ± 61</td>
<td>1346 ± 94</td>
<td>1298 ± 137</td>
<td>1140 ± 97</td>
<td>1447 ± 159</td>
<td>839 ± 78*</td>
</tr>
<tr>
<td>90–120</td>
<td>1213 ± 173</td>
<td>1384 ± 53</td>
<td>1278 ± 63</td>
<td>1819 ± 425</td>
<td>1047 ± 105</td>
<td>1571 ± 412</td>
<td>632 ± 99*</td>
</tr>
<tr>
<td>120–150</td>
<td>943 ± 105</td>
<td>1408 ± 113†</td>
<td>1183 ± 96</td>
<td>1357 ± 64</td>
<td>1070 ± 154</td>
<td>1047 ± 93</td>
<td>713 ± 88*</td>
</tr>
</tbody>
</table>

Values are means ± SE (n = 6), except in HyperLoad-30 and IsoLoad-30 (n = 7). Saline was infused for 90 min from t = 30 min to t = 120 min. *Significantly different from preinfusion level (P < 0.05); †significantly different from control series (P < 0.05).
ANG II, because plasma levels were inversely correlated with renal sodium excretion. Figure 3 shows the relationship between mean arterial blood pressure, plasma ANG II, and renal sodium excretion, with three points from each experiment: preinfusion, end-infusion, and recovery values. Sodium excretion was increased only when the plasma levels of ANG II were <10 pg/ml, and this relationship does not appear to be affected by mean arterial blood pressure changes in the range of 95–125 mmHg. These results support a number of previous conclusions from both animal and human investigations (2, 4, 21, 23) that the decrease in plasma levels of ANG II is a major factor determining sodium excretion during salt loading. The present study was not designed to evaluate in detail the immediate effects of a decrease in plasma ANG II on renal sodium handling; however, the intrarenal effects of ANG II have been studied intensively in micropuncture experiments. The overall effect of ANG II on proximal tubular function in vivo is still unclear, but recently it was reported that ANG II may directly stimulate sodium reabsorption in the distal tubule of the rat (26). This may explain at least part of the natriuretic effect of a decrease in plasma ANG II under conditions of constant arterial blood pressure and GFR. Another possible intrarenal mechanism is that the decrease in ANG II allows intrarenal hydrostatic pressure to rise, thereby inhibiting tubular sodium reabsorption (6).

The explanation for the fall in the activity of the renin-angiotensin system in our experiments is not straightforward, at least not when it occurs without changes in GFR or blood pressure. Plasma ANG II is generated by renin and converting enzyme. Renin secretion is regulated by 1) changes in renal perfusion pressure (14), 2) changes in sodium chloride concentration at the macula densa (24), and 3) changes in renal nerve activity (19). During HyperLoad-20 and IsoLoad-20 experiments, an increase in renal perfusion pressure cannot directly explain the decrease in renin activity, because mean arterial blood pressure did not change. However, regulation of renin secretion by changes in renal perfusion pressure is a complex relationship involving transmural pressure, tangential wall tension, and the arteriolar diameter at the level of the renin-secreting juxtaglomerular cells. Thus it is very difficult to completely dismiss the intrarenal vascular baroreceptor mechanism in the suppression of renin secretion in this study. Increases in sodium delivery to macula densa may have occurred both in Hyper-Load-20 and IsoLoad-20 series and elicited decreases in renin secretion and ANG II production. In both series, the filtered load of Na+ was increased: in HyperLoad-20 experiments, plasma sodium increased by 1% and GFR was unchanged; in the IsoLoad-20 series, GFR increased by ~8%, whereas plasma sodium was unchanged. If the macula densa-mediated mechanism was responsible in the former case, then it must be very sensitive and capable of reacting to a 1% increase in filtered load. However, different and very specific experimental approaches are required to evaluate possible relations between filtered load, macula densa electrolyte concentrations, and renin secretion operating at such small deviations.

Changes in renal sympathetic nerve activity may also have been involved in the natriuresis seen during the present experiments. A decrease in renal sympathetic nerve activity is a contributory factor to the natriuresis observed after volume expansion (for review, see Ref. 9) also in conscious dogs (18). Changes in renal sympathetic nerve activity may affect sodium excretion either via changes in renin secretion or by directly affecting tubular transport. The latter was clearly demonstrated in conscious dogs by Persson et al. (20). In our study, sympathetic nerve activity is assumed to be low, because control heart rates were ~55 beats/min. Therefore, withdrawal of renal sympathetic nerve activity under the present circumstances most likely was a mechanism left with only a narrow range of operation. However, we cannot rule out the possibility that a decrease in renal sympathetic nerve activity, small as it might have been, nevertheless played a significant role in the natriuresis seen during salt loading in this study.

Other factors may have been involved but appear even more unlikely. Changes in atrial natriuretic peptide (ANP) may have affected sodium excretion during nonhypertensive salt loading. Plasma ANP was not measured in the present experiments, because in a previous study (4) it was found that plasma ANP was not elevated during hypertonic infusion and made only a small (14%) increase during isotonic infusion of 60 µmol·kg⁻¹·min⁻¹, i.e., 2–10 times the stimulus inten-
of the 6 µmol·kg⁻¹ body fluid osmolality generated by the administration occurred while plasma osmolality only tended to load-6 series that a 33% increase in plasma vasopres- in plasma osmolality. First, it was found in the Hyper- vasopressin secretion is extremely sensitive to changes results illustrate that, above a possible threshold, low plasma osmolality levels of 304 mosmol/kg. The experiments, because observations were not made be- cause osmoreceptors may play a role in mediating the natriuretic response to a hypertonic sodium load, but further investigation is necessary to illustrate the importance and the effector mechanisms in osmoregulated natriuresis.

Plasma osmolality is the major regulator of vasopres- sin secretion (for review, see Ref. 3). By intracarotid infusions of sodium chloride solutions of different tonic- ity in conscious dogs, Wade et al. (25) showed that after a threshold, plasma vasopressin increased with increasing jugular plasma osmolality in a linear relationship. Our results in this and a previous study (4) support this linear relationship. The threshold phenomenon for vasopressin secretion was not addressed by the present experiments, because observations were not made below plasma osmolality levels of 304 mosmol/kg. The results illustrate that, above a possible threshold, vasopressin secretion is extremely sensitive to changes in plasma osmolality. First, it was found in the Hyper-Load-6 series that a 33% increase in plasma vasopres- sin occurred while plasma osmolality only tended to increase by ~1 mosmol/kg. The calculated increase in body fluid osmolality generated by the administration of the 6 µmol·kg⁻¹·min⁻¹ load is 1.5 mosmol/kg. Conse- quently, vasopressin secretion responds to plasma osmo- lality changes, which are undetectable by conventional freezing-point osmometry, which, with plasma samples, operates with coefficients of variation of 0.25–0.40%. Second, the results indicate that the slope of the relationship is ~0.5, i.e., that, for each milliosmole, plasma osmolality increases plasma vasopressin by 0.5 pg/ml. This appears to be a very steep slope (see Ref. 25). It is possible that the present protocol, which included infusions of strongly hypertonic saline solutions at very low rates, is more appropriate for detection of the parameters of the osmoregulatory control system than previous procedures.

Perspectives

The present study demonstrates that mean arterial blood pressure is very sensitive to slow sodium loading in conscious dogs. This sensitivity appears to be different from that of humans, because sodium chloride may be infused at considerably higher rates in humans without any measured change in mean arterial blood pressure. A comparative investigation of the sensitivity of blood pressure regulation to the rate of infusion of NaCl appears warranted, because species difference (dog to human), if present to any sizable extent, is a necessary prerequisite for appropriate interpretation of quantitative results. The study shows that, even in dogs, natriuresis after a physiological sodium load may easily occur without changes in mean arterial blood pressure and GFR rate and that this natriuresis is inversely associated with plasma levels of ANG II. Therefore, withdrawal of ANG II may be an important component of any volume expansion natriuresis. Acute and chronic nonhypertensive sodium loading may provide detailed quantitative knowledge of the regulatory mechanisms in sodium and water homeostasis, particu- larly the main sensory mechanism behind and the specific actions of ANG II withdrawal capable of regulat- ing renal sodium excretion by at least one order of magnitude without changes in filtration rate. Such information is crucially important to the understand- ing of normal body fluid regulation and of different pathophysiological conditions in sodium and water handling, i.e., arterial hypertension and congestive heart failure.

The expert technical assistance of Sigurd K. Hansen in the dog laboratory and Birthe Lynderup Christensen, Trine Eidsvold, Inge H. Pedersen, and Barbara Sørensen with the analyses is gratefully appreciated. Aprotinine was kindly provided by Novo Nordisk. Drs. Niels-Henrik Holstein-Rathsø and Paul Peter Lysøe provided valuable insight with regard to the interpretation of the results.

The work was supported by grants from The Danish Medical Research Council, the Novo Nordisk Foundation, and the Velux Foundation.

Address for reprint requests and other correspondence: P. Bie, Dept. of Physiology and Pharmacology, University of Odense, 21 Winslawparken, DK-5000 Odense, Denmark (E-mail: bie@mbmed. sdu.dk).

Received 15 March 1999; accepted in final form 26 July 1999.